

Renal Intelligence Report

CKD · ESRD · Dialysis · Transplant · Diabetic Kidney Disease

● LIVE INGEST

Last refresh — 07 May 2026 23:47:44Z

Window — last 90 days

Pipeline — tools/scout-ingest

<p>TRACKED SIGNALS</p> <p>1,692</p> <p>Public, source-cited</p>	<p>SOURCES ACTIVE</p> <p>4 / 6</p> <p>Of 6 wired</p>	<p>COMPANIES MONITORED</p> <p>41</p> <p>Atlas-linked dossiers</p>	<p>CRITICAL / HIGH</p> <p>188</p> <p>Material signals (90d)</p>
--	---	--	--

RISK REGISTER · THE COST OF SEEING LATE Adversarial verification scope

Three exposures every renal portfolio carries today.

Reimbursement Cycle Risk

CMS ETC and value-based kidney care arrangements are repricing roughly \$30B in dialysis run-rate. The dialysis-to-home transition reshapes the reimbursement floor for the dominant providers. Live formulary, MAC bulletin, and CMS LCD signals are tracked across the indexer.

CALIBRATING · NEXT REFRESH

DKD Intersection Risk

Roughly 40% of CKD patients are diabetic. SGLT2 inhibitors, Kerendia, and the GLP-1 cardiometabolic franchise reshape both indications simultaneously. PubMed signals indexed in the 90-day window quantify the cross-indication exposure.








1,000

Sovereign Procurement Risk

KSA, GCC, and MENA renal providers and manufacturers under continuous monitoring. Vision 2030 nephrology capacity buildout is in motion — missing a procurement cycle means missing the horizon.

5 / 41

What we are watching

FDA openFDA		333
ClinicalTrials.gov		215
PubMed		1000
SEC EDGAR		144
CMS LCD		0
USPTO Patents		0
Manufacturer Pipelines		0

Top 10 by severity and recency

PUBMED CRITICAL 2026-05-02

Normothermic regional perfusion in kidney transplants with donors after controlled circulatory death: Functional benefits and safety in older recipients.

Toapanta N

Normothermic regional perfusion in kidney transplants with donors after controlled circulatory death: Functional benefit...

[PubMed \(NCBI E-utilities\) ↗](#)

PUBMED CRITICAL 2026-04-29

LMT328, a sulfiredoxin inhibitor, induces preferential cancer cell death and tumor regression via oxidative stress.

Lee GR

LMT328, a sulfiredoxin inhibitor, induces preferential cancer cell death and tumor regression via oxidative stress.

[PubMed \(NCBI E-utilities\) ↗](#)

PUBMED CRITICAL 2026-04-27

Decreased incidence of acute kidney injury following donation after circulatory death orthotopic liver transplantation using normothermic machine perfusion.

Fah MK

Decreased incidence of acute kidney injury following donation after circulatory death orthotopic liver...

[PubMed \(NCBI E-utilities\) ↗](#)

PUBMED CRITICAL 2026-04-25

Pharmacological blood-pressure lowering for the prevention of cardiovascular disease and death across the full spectrum of chronic kidney disease severity: an individual-participant data meta-analysis.

Zeng G

Pharmacological blood-pressure lowering for the prevention of cardiovascular disease and death across the full spectru...

[PubMed \(NCBI E-utilities\) ↗](#)

PUBMED CRITICAL 2026-04-24

Electronic health record dynamic features for in-hospital death among chronic kidney disease patients.

Li J

Electronic health record dynamic features for in-hospital death among chronic kidney disease patients.

[PubMed \(NCBI E-utilities\) ↗](#)

PUBMED CRITICAL 2026-04-01

A Prediction Model for Risk of Death in Kidney Transplant Recipients.

Debiais-Deschamps C

A Prediction Model for Risk of Death in Kidney Transplant Recipients.

[PubMed \(NCBI E-utilities\) ↗](#)

PUBMED CRITICAL 2026-03-25

Fatal Outcome Following Polysubstance Use: A Case Report of Rhabdomyolysis, Acute Kidney Injury, and Deep Vein Thrombosis.

Stoeva-Grigorova S

Fatal Outcome Following Polysubstance Use: A Case Report of Rhabdomyolysis, Acute Kidney Injury, and Deep Vein...

PubMed (NCBI E-utilities) ↗

PUBMED CRITICAL 2026-01-01

Fatal Escherichia coli Necrotizing Fasciitis in a Patient With End-Stage Renal Disease and Type 2 Diabetes Mellitus.

Clark CA

Fatal Escherichia coli Necrotizing Fasciitis in a Patient With End-Stage Renal Disease and Type 2 Diabetes Mellitus.

PubMed (NCBI E-utilities) ↗

PUBMED CRITICAL 2026-01-01

Fatal metformin-associated lactic acidosis in a healthy woman after massive overdose.

Unal Kaya E

Fatal metformin-associated lactic acidosis in a healthy woman after massive overdose.

PubMed (NCBI E-utilities) ↗

PUBMED CRITICAL 2026-01-01

Time to Death and Donation After Circulatory Death Kidney Transplant Outcomes: Opportunities for Improved Utilization in the United States.

Amarnath DR

Time to Death and Donation After Circulatory Death Kidney Transplant Outcomes: Opportunities for Improved Utilizatio...

PubMed (NCBI E-utilities) ↗

Reimbursement watchlist

CMS ETC & VALUE-BASED KIDNEY CARE · 2025-2026

The dialysis-to-home transition is reshaping the renal economics base.

Coverage and formulary decisions on SGLT2 inhibitors with cardiorenal indications, Kerendia for diabetic kidney disease, and the CMS End-Stage Renal Disease Treatment Choices (ETC) model are in active rewrite. Value-based kidney care arrangements at DaVita, Fresenius, and integrated providers are repricing the dialysis floor. AimwellBio's CMS LCD ingest is in calibration; full coverage activates on the next refresh cycle. Manufacturer commentary, MAC bulletins, and proposed-policy comment periods will populate this surface as the indexer comes online.

Saudi Arabia · Vision 2030

SOVEREIGN VECTOR · KSA / GCC / MENA

Vision 2030 nephrology capacity is in active buildout. The procurement window crosses dialysis, transplant, and diabetic kidney disease.

The GCC and MENA cluster represents the highest-density sovereign-procurement opportunity for AimwellBio's renal intelligence layer. SFDA approvals, MOH formulary movements, dialysis capacity expansion, transplant program disclosures, and cross-border clinical infrastructure across Riyadh, Abu Dhabi, and Amman are already trackable through the indication-aware pipeline.

Decisions of this scale — coverage policy, dialysis-modality procurement, transplant network expansion, and SGLT2 / Kerendia formulary placement — cannot rest on a single source or vendor pipeline page. They require an adversarial verification layer with origin URLs, fetch timestamps, and reproducible claims for every signal.

\$100B+

U.S. CKD/ESRD Medicare line

5 / 40

Sovereign-tagged renal anchors monitored

~\$30B

U.S. dialysis run-rate under reimbursement reshape

7

Public sources triangulated per signal class

SOVEREIGN ROSTER · KSA / GCC / MENA

<p>King Faisal Specialist Hospital Nephrology Riyadh, SA</p> <p>KSA</p>	<p>SPIMACO Renal Riyadh, SA</p> <p>KSA</p>	<p>Cleveland Clinic Abu Dhabi Nephrology Abu Dhabi, AE</p> <p>GCC</p>	<p>NMC Healthcare Renal Abu Dhabi, AE</p> <p>GCC</p>	<p>Hikma Renal Amman, JO</p> <p>MENA</p>
--	---	--	---	---

Monitored issuers and operators


<p>Cleveland Clinic Abu Dhabi Nephrology Abu Dhabi, AE</p> <p>GCC</p>	<p>Hikma Renal HIK Amman, JO</p> <p>MENA</p>	<p>King Faisal Specialist Hospital Nephrology Riyadh, SA</p> <p>KSA</p>
<p>NMC Healthcare Renal Abu Dhabi, AE</p> <p>GCC</p>	<p>SPIMACO Renal Riyadh, SA</p> <p>KSA</p>	<p>Akebia Therapeutics AKBA Cambridge, MA</p> <p>BIOTECH</p>
<p>Ardelyx ARDX Waltham, MA</p> <p>BIOTECH</p>	<p>AstraZeneca Renal AZN Cambridge, UK</p> <p>BIGPHARMA</p>	<p>Baxter Renal Care BAX Deerfield, IL</p> <p>MEDTECH</p>
<p>Bayer Renal (Kerendia) Leverkusen, DE</p> <p>BIGPHARMA</p>	<p>Boehringer Ingelheim Renal Ingelheim, DE</p> <p>BIGPHARMA</p>	<p>Calliditas Therapeutics CALT Stockholm, SE</p> <p>BIOTECH</p>
<p>CareDx CDNA Brisbane, CA</p> <p>MEDTECH</p>	<p>Chinook Therapeutics (Novartis) NVS Seattle, WA</p> <p>BIOTECH</p>	<p>Cricket Health (Interwell) Boston, MA</p> <p>EMERGING</p>
<p>DaVita DVA Denver, CO</p> <p>BIGPHARMA</p>	<p>Diality Irvine, CA</p> <p>EMERGING</p>	<p>Dialysis Clinic Inc. Nashville, TN</p> <p>BIGPHARMA</p>
<p>Fresenius Medical Care FMS Bad Homburg, DE</p> <p>BIGPHARMA</p>	<p>Goldfinch Bio Cambridge, MA</p> <p>BIOTECH</p>	<p>GSK Renal GSK London, UK</p> <p>BIGPHARMA</p>
<p>Healthmap Solutions Tampa, FL</p> <p>EMERGING</p>	<p>Medtronic Renal Care MDT Minneapolis, MN</p> <p>MEDTECH</p>	<p>Mineralys Therapeutics MLYS Radnor, PA</p> <p>BIOTECH</p>
<p>Monogram Health Brentwood, TN</p> <p>EMERGING</p>	<p>Natera Renal NTRA Austin, TX</p> <p>MEDTECH</p>	<p>Nipro Medical Osaka, JP</p> <p>MEDTECH</p>
<p>Novartis Renal NVS Basel, CH</p> <p>BIGPHARMA</p>	<p>Otsuka Renal (Jinarc) Tokyo, JP</p> <p>BIGPHARMA</p>	<p>Outset Medical OM San Jose, CA</p> <p>MEDTECH</p>

ProKidney PROK Winston-Salem, NC BIOTECH	Quanta Dialysis Alcester, UK EMERGING	Sanofi Transplant SNY Paris, FR BIGPHARMA
Satellite Healthcare San Jose, CA BIGPHARMA	Somatus McLean, VA EMERGING	Strive Health Denver, CO EMERGING
Travere Therapeutics TVTX San Diego, CA BIOTECH	U.S. Renal Care Plano, TX BIGPHARMA	Veloxis Pharmaceuticals Cary, NC BIOTECH
Vera Therapeutics VERA Brisbane, CA BIOTECH	Visterra Waltham, MA BIOTECH	

06 - 90-DAY SIGNAL TIMELINE

Hover any bar for week detail

Volume & cadence of public disclosure



METHODOLOGY

This report is generated from a live ingest pipeline (`tools/scout-ingest`). Sources: FDA openFDA, ClinicalTrials.gov v2 API, PubMed E-utilities, SEC EDGAR, CMS Medicare Coverage Database, USPTO Patent Center, and manufacturer pipeline pages. Updated 07 May 2026 23:47:44Z. Every signal carries source URL and fetch timestamp; click any card to view origin.

Confidence framework. Source-backed > pattern-inferred > model-hypothesis > speculative. This report contains source-backed signals only. Pattern-inferred and model-hypothesis tiers are surfaced only inside member dashboards with explicit provenance flags.

Limitations. This is a public, ToS-compliant view. Closed-source manufacturer disclosures, ministry tenders, and private regulatory correspondence are out of scope for this surface. Members access an extended view with partner intelligence subject to NDA. Sovereign-tagged companies (KSA, GCC, MENA)

reflect publicly observable regional headquarters; ministry-procurement detail is reserved for the partner intelligence surface.